A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?

Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identification of distinct molecular alterations with corresponding targeted therapies is modifying this thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Aimar, Giacomo, Paratore, Chiara, Zichi, Clizia, Marino, Donatella, Sperti, Elisa, Caglio, Andrea, Gamba, Teresa, De Vita, Francesca, Di Maio, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400771/
https://www.ncbi.nlm.nih.gov/pubmed/36045702
http://dx.doi.org/10.37349/etat.2021.00056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400771/
https://www.ncbi.nlm.nih.gov/pubmed/36045702
http://dx.doi.org/10.37349/etat.2021.00056

Ejemplares similares